TABLE 1

Association studies of MTNR1B rs10830963 in the Danish population-based Inter99 sample, in individuals sampled at Steno Diabetes Center, and in the French DESIR cohort in relation to glucose tolerance status

Glucose toleranti-IFGi-IGTBoth IFG and IGTType 2 diabetes
n(men/women)4,905 (2,277/2,628)485 (356/129)464 (196/268)201 (130/71)1,948 (1,200/748)
CC2,644 (53.9%)196 (40.4%)282 (60.8%)106 (52.7%)1,002 (51.4%)
CG1,913 (39%)230 (47.4%)151 (32.5%)66 (32.8%)776 (39.8%)
GG348 (7.1%)59 (12.2%)31 (6.7%)29 (14.4%)170 (8.7%)
G-allele frequency (%)26.636.023.030.828.6
OR per G-allele (95% CI)1.64 (1.41–1.89)0.85 (0.72–1.00)1.35 (1.08–1.69)1.23 (1.10–1.37)
Padd5.5 × 10−110.0510.00850.00036

French DESIR cohort (n = 3,411)Incidence of IFG (n = 334)Incidence of type 2 diabetes (n = 183)
Hazard ratio (95% CI)1.24 (1.06–1.45)1.02 (0.80–1.25)
Padd0.0070.87
  • In the Danish study populations, data are n (%), number of subjects stratified according to MTNR1B rs10830963, G-allele frequency in %, and OR (95% CI) per allele. P values compare genotype distribution between case subjects (i-IFG, i-IGT, both IFG and IGT, and type 2 diabetes), and glucose-tolerant control subject applying an additive genetic model while adjusting for age, sex, and BMI. In the French DESIR cohort, the incidence of IFG or diabetes was defined as fasting plasma glucose ≥6.1 mmol/l or treatment with antidiabetic agents after a 9-year follow-up period.